|
gptkbp:instanceOf
|
antineoplastic agent
anthracycline antibiotic
|
|
gptkbp:administeredBy
|
intravenous injection
|
|
gptkbp:affiliatedWith
|
antineoplastic agents
|
|
gptkbp:approvalYear
|
1974
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:chemicalFormula
|
C27H29NO11
|
|
gptkbp:color
|
red
|
|
gptkbp:contraindication
|
severe cardiac disease
|
|
gptkbp:discoveredBy
|
gptkb:Farmitalia
|
|
gptkbp:discoveredIn
|
1967
|
|
gptkbp:eliminationHalfLife
|
20-48 hours
|
|
gptkbp:genericName
|
gptkb:doxorubicin
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Adriamycin
|
|
gptkbp:mechanismOfAction
|
intercalates DNA
inhibits DNA replication
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:origin
|
gptkb:Streptomyces_peucetius
|
|
gptkbp:otherName
|
gptkb:hydroxydaunorubicin
Caelyx (liposomal form)
Rubex
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:riskFactor
|
gptkb:secondary_leukemia
heart failure
|
|
gptkbp:sideEffect
|
nausea
vomiting
hair loss
cardiotoxicity
myelosuppression
|
|
gptkbp:usedFor
|
gptkb:cancer
leukemia
bladder cancer
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Streptomyces_species
|
|
gptkbp:bfsLayer
|
6
|